Recent Advances in the Treatment of Hemophilia: A Review

References

• Jang JH, Seo JY, Bang SH, et al. Establishment of reference intervals for von Willebrand factor antigen and eight coagulation factors in a Korean population following the Clinical and Laboratory Standards Institute guidelines. Blood Coagul Fibrinolysis. 2010;21:251–255. doi:10.1097/MBC.0b013e3283367931
   Web of Science ®Google Scholar
• Mannucci PM, Franchini M. Is haemophilia B less severe than haemophilia A? Haemophilia. 2013;19:499–502. doi:10.1111/hae.12133
   PubMed Web of Science ®Google Scholar
• Melchiorre D, Linari S, Manetti M, et al. Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A. Haematologica. 2016;101:219–225. doi:10.3324/haematol.2015.133462
   PubMed Web of Science ®Google Scholar
• Franchini M, Mannucci PM. Haemophilia B is clinically less severe than haemophilia A: further evidence. Blood Transfus. 2018;16:121–122. doi:10.2450/2016.0158-16
   PubMed Web of Science ®Google Scholar
• Santagostino E, Fasulo MR. Hemophilia a and hemophilia B: different types of diseases? Semin Thromb Hemost. 2013;39:697–701. Review. doi:10.1055/s-0033-1353996
   PubMed Web of Science ®Google Scholar
• van Miert JH, Hop H, Borjas-Howard JF, Meijer K. A milder clinical course for severe hemophilia B: a true or biased effect? Haematologica. 2016;101:e266. doi:10.3324/haematol.2016.147298
   Web of Science ®Google Scholar
• Tagariello G, Iorio A, Santagostino E, et al. Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood. 2009;114:779–784. doi:10.1182/blood-2009-01-195313
   PubMed Web of Science ®Google Scholar
• Belvini D, Salviato R, Radossi P, et al. Molecular genotyping of the Italian cohort of patients with hemophilia B. Haematologica. 2005;90:635–642.
   PubMed Web of Science ®Google Scholar
• Lane S. Haemorrhagic diathesis. Successful transfusion of blood. Lancet. 1840;35:185–188. doi:10.1016/S0140-6736(00)40031-0
   Google Scholar
• Ingram GI. The history of haemophilia. Haemophilia. 1997;3(Suppl 1):5–15. doi:10.1111/j.1365-2516.1997.tb00168.x
   Web of Science ®Google Scholar
• Bloamback B, Bloamback M, Nilsson IM. Note on the purification of human antihemophilic globulin. Acta Chem Scand. 1958;12:1878. doi:10.3891/acta.chem.scand.12-1878
   Google Scholar
• Pool JG, Gershgold EJ, Pappenhagen AR. High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate. Nature. 1964;203:312. doi:10.1038/203312a0
   PubMed Web of Science ®Google Scholar
• Pool JG, Shannon AE. Production of high-potency concentrates of antihemophilic globulin in a closed-bag system. N Engl J Med. 1965;273:1443–1447. doi:10.1056/NEJM196512302732701
   PubMed Web of Science ®Google Scholar
• Morfini M. In vitro characteristics of highly purified Factor VIII concentrates. Ann Hematol. 1991;63:123–125. doi:10.1007/BF01703241
   Web of Science ®Google Scholar
• Kasper CK, Kipnis SA. Hepatitis and clotting-factor concentrates. JAMA. 1972;221:510. doi:10.1001/jama.1972.03200180052024
   PubMed Web of Science ®Google Scholar
• Morfini M, Rafanelli D, Longo G, et al. Hepatitis-free interval after clotting factor therapy in first infused haemophiliacs. Thromb Haemost. 1986;56:268–270. doi:10.1055/s-0038-1661664
   Web of Science ®Google Scholar
• Evatt BL, Gomperts ED, McDougal JS, Ramsey RB. The coincidental appearance of LAV/HTLV-III antibodies in hemophiliacs and the onset of the AIDS epidemic. N Engl J Med. 1985;312:483–486. doi:10.1056/NEJM198502213120805
   PubMed Web of Science ®Google Scholar
• Ragni MV, Tegtmeier GE, Levy JA, et al. AIDS retrovirus antibodies in hemophiliacs treated with factor VIII or factor IX concentrates, cryoprecipitate, or fresh frozen plasma: prevalence, seroconversion rate, and clinical correlations. Blood. 1986;67:592–595. doi:10.1182/blood.V67.3.592.592
   Web of Science ®Google Scholar
• Evatt BL. The tragic history of AIDS in the hemophilia population, 1982–1984. J Thromb Haemost. 2006;4:2295–2301. doi:10.1111/j.1538-7836.2006.02213.x
   PubMed Web of Science ®Google Scholar
• Morfini M, Mannucci PM, Mariani G, et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scand J Haematol. 1976;16:41–47. doi:10.1111/j.1600-0609.1976.tb01115.x
   PubMedGoogle Scholar
• Ghirardini A, Schinaia N, Chiarotti F, et al. Epidemiology of hemophilia and of HIV infection in Italy. GICC. Gruppo Italiano Coagulopatie Congenite. J Clin Epidemiol. 1994;47:1297–1306. doi:10.1016/0895-4356(94)90135-X
   Web of Science ®Google Scholar
• Mannucci PM. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates. Vox Sang. 1993;64:197–203. doi:10.1111/j.1423-0410.1993.tb03055.x
   PubMed Web of Science ®Google Scholar
• Bartolomei Corsi O, Azzi A, Morfini M, et al. Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates. J Med Virol. 1988;25:165–170. doi:10.1002/jmv.1890250206
   PubMed Web of Science ®Google Scholar
• Santagostino E, Mannucci PM, Gringeri A, et al. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization. Transfusion. 1997;37:517–522. doi:10.1046/j.1537-2995.1997.37597293884.x
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Gdovin S, Gringeri A, et al. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group. Ann Intern Med. 1994;120:1–7. doi:10.7326/0003-4819-120-1-199401010-00001
   PubMed Web of Science ®Google Scholar
• Azzi A, De Santis R, Morfini M, et al. TT virus contaminates first-generation recombinant factor VIII concentrates. Blood. 2001;98:2571–2573. doi:10.1182/blood.V98.8.2571
   PubMed Web of Science ®Google Scholar
• Gomperts E, Lundblad R, Adamson R. The manufacturing process of recombinant factor VIII, Recombinate. Transfus Med Rev. 1992;6:247–251. doi:10.1016/S0887-7963(92)70175-8
   Google Scholar
• Bray GL, Gomperts ED, Courter S, et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood. 1994;83:2428–2435.
   PubMed Web of Science ®Google Scholar
• Morfini M, Rapisarda CAP. Safety of recombinant coagulation factors in treating hemophilia. Expert Opin Drug Saf. 2019;18:75–85. doi:10.1080/14740338.2019.1574743
   PubMed Web of Science ®Google Scholar
• White G 2nd, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost. 1997;78:261–265. doi:10.1055/s-0038-1657536
   PubMed Web of Science ®Google Scholar
• Pittman DD, Alderman EM, Tomkinson KN, et al. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood. 1993;81:2925. doi:10.1182/blood.V81.11.2925.2925
   PubMed Web of Science ®Google Scholar
• Morfini M, Zanon E. Emerging drugs for the treatment of hemophilia A and B. Expert Opin Emerg Drugs. 2016;21:301–313. doi:10.1080/14728214.2016.1220536
   PubMed Web of Science ®Google Scholar
• Schwarzinger I, Pabinger I, Korninger C, et al. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. Am J Hematol. 1987;24:241–245. doi:10.1002/ajh.2830240303
   PubMed Web of Science ®Google Scholar
• Ehrenforth S, Kreuz W, Scharrer I, Kornhuber B. Factor VIII inhibitors in haemophiliacs. Lancet. 1992;340:253. doi:10.1016/0140-6736(92)90530-G
   PubMed Web of Science ®Google Scholar
• Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet. 1992;339:594–598. doi:10.1016/0140-6736(92)90874-3
   PubMed Web of Science ®Google Scholar
• Lusher JM. First and second-generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development. Semin Thromb Hemost. 2002;28:273–276. doi:10.1055/s-2002-32662
   PubMed Web of Science ®Google Scholar
• Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med. 1993;328:453–459. doi:10.1056/NEJM199302183280701
   PubMed Web of Science ®Google Scholar
• Kreuz W, Ettingshausen CE, Zyschka A, et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost. 2002;28:285–290. doi:10.1055/s-2002-32664
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016;374:2054–2064. doi:10.1056/NEJMoa1516437
   PubMed Web of Science ®Google Scholar
• Calvez T, Chambost H, d’Oiron R, et al. Analyses of the France Coag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A. Haematologica. 2018;103:179–189. doi:10.3324/haematol.2017.174706
   PubMed Web of Science ®Google Scholar
• Ljung R, Auerswald G, Benson G, et al. Inhibitors in haemophilia A and B: management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients. Eur J Haematol. 2019;102:111–122. doi:10.1111/ejh.13193
   PubMed Web of Science ®Google Scholar
• Thorland EC, Drost JB, Lusher JM, et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia. 1999;5:101–105. doi:10.1046/j.1365-2516.1999.00303.x
   Web of Science ®Google Scholar
• Jones P, Fearns M, Forbes C, Stuart J. Haemophilia A home therapy in the United Kingdom 1975–6. Br Med J. 1978;1:1447–1450. doi:10.1136/bmj.1.6125.1447
   Web of Science ®Google Scholar
• van Meegeren ME, Roosendaal G, Jansen NW, et al. Blood-induced joint damage: the devastating effects of acute joint bleeds versus micro-bleeds. Cartilage. 2013;4:313–320. doi:10.1177/1947603513497569
   PubMed Web of Science ®Google Scholar
• van Vulpen LF, van Meegeren ME, Roosendaal G, et al. Biochemical markers of joint tissue damage increase shortly after a joint bleed; an explorative human and canine in vivo study. Osteoarthritis Cartilage. 2015;23:63–69. doi:10.1016/j.joca.2014.09.008
   PubMed Web of Science ®Google Scholar
• Aledort LM, Haschmeyer RH, Pettersson HJ. A longitudinal study of orthopedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. Intern Med. 1994;236:391–399.
   Google Scholar
• Soucie JM, Monahan PE, Kulkarni R, et al. The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B. Blood Adv. 2018;2:2136–2144. doi:10.1182/bloodadvances.2018020552
   Web of Science ®Google Scholar
• den Uijl IEM IEM, Fischer K, Van Der Bom JG, et al. Plug analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia. 2011;17:41–44. doi:10.1111/j.1365-2516.2010.02383.x
   Web of Science ®Google Scholar
• Gringeri A, Ewenstein B, Reininger A. The burden of bleeding in haemophilia: is one bleed too many? Haemophilia. 2014;20:459–463. doi:10.1111/hae.12375
   PubMed Web of Science ®Google Scholar
• Valentino LA, Hakobyan N, Enockson C. Blood–induced joint disease: the confluence of dysregulated oncogenes, inflammatory signals, and angiogenic cues. Semin Hematol. 2008;45(Suppl.1):S50–7. doi:10.1053/j.seminhematol.2008.03.017
   Web of Science ®Google Scholar
• Zetterberg E, Palmblad J, Wallensten R, et al. Angiogenesis is increased in advanced haemophilic joint disease and characterised by normal pericyte coverage. Eur J Haematol. 2014;92:256–262. doi:10.1111/ejh.12227
   PubMed Web of Science ®Google Scholar
• Van Creveld S. Prophylaxis of joint hemorrhages in hemophilia. Acta Haematol. 1969;41:206–214. doi:10.1159/000208852
   PubMed Web of Science ®Google Scholar
• Blancette VS, Key NS, Ljung LR, et al. Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. J Thromb Haemost. 2014;12:1935–1939. doi:10.1111/jth.12672
   Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535–544. doi:10.1056/NEJMoa067659
   PubMed Web of Science ®Google Scholar
• Gringeri A, Lundin B, von Mackensen S, et al.; ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost. 9;2011:700–710. doi:10.1111/j.1538-7836.2011.04214.x
   PubMed Web of Science ®Google Scholar
• Tagliaferri A, Feola G, Molinari AC, et al.; POTTER Study Group. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study. Thromb Haemost. 114;2015:35–45. doi:10.1160/TH14-05-0407
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Lundin B, Funk S, et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Thromb Haemost. 2017;15:2115–2124. doi:10.1111/jth.13811
   Web of Science ®Google Scholar
• Manco-Johnson MJ, Sanders J, Ewing N, et al.; TEEN/TWEN Study Group. Consequences of switching from prophylactic treatment to on-demand treatment in late teens and early adults with severe haemophilia A: the TEEN/TWEN study. Haemophilia. 19;2013:727–735. doi:10.1111/hae.12177
   PubMed Web of Science ®Google Scholar
• Nijdam A, Foppen W, De Kleijn P, et al. Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates. Thromb Haemost. 2016;115:931–938. doi:10.1160/TH15-08-0637
   Web of Science ®Google Scholar
• Valentino LA, Pipe SW, Collins PW, et al. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis. Haemophilia. 2016;22:514–520. doi:10.1111/hae.12905
   PubMed Web of Science ®Google Scholar
• Gabrielsson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. 4th ed. Stockholm: Swedish Pharmaceutical Press; 2006.
   Google Scholar
• Riviere JE. Comparative Pharmacokinetics: Principles, Techniques & Application. Wiley-Blacwell ed. Jowa State University Press; 2011:351–353.
   Google Scholar
• Bjorkman S, Oh M, Spotts G, et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood. 2012;119:612–618. doi:10.1182/blood-2011-07-360594
   PubMed Web of Science ®Google Scholar
• Lunghi B, Bernardi F, Martinelli N, et al. Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates. J Thromb Haemost. 2019;17:1288–1296. doi:10.1111/jth.14473
   Web of Science ®Google Scholar
• Garcia-Martínez I, Borràs N, Martorell M, et al. Common genetic variants in ABO and CLEC4M modulate the pharmacokinetics of recombinant FVIII in severe hemophilia A patients. Thromb Haemost. 2020;120:1395–1406. doi:10.1055/s-0040-1714214
   Web of Science ®Google Scholar
• Ogiwara K, Swystun LL, Paine AS, et al. Factor VIII pharmacokinetics associates with genetic modifiers of VWF and FVIII clearance in an adult hemophilia A population. J Thromb Haemost. 2021;19:654–663. doi:10.1111/jth.15183
   PubMed Web of Science ®Google Scholar
• Lunghi B, Morfini M, Martinelli N, et al. Polymorphisms in the asialoglycoprotein receptor minor subunit gene (ASGR2) contribute to pharmacokinetics of factor VIII concentrates in Hemophilia A; March 3, 2021.
   Google Scholar
• Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glyco-PEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood. 2011;118:2695–2701. doi:10.1182/blood-2011-02-335596
   PubMed Web of Science ®Google Scholar
• Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 2012;120:2405–2411. doi:10.1182/blood-2012-05-429688
   PubMed Web of Science ®Google Scholar
• Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369:2313–2323. doi:10.1056/NEJMoa1305074
   PubMed Web of Science ®Google Scholar
• Tiede A, Brand B, Fischer R, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013;11:670–678. doi:10.1111/jth.12161
   PubMed Web of Science ®Google Scholar
• Coyle TE, Reding MT, Lin JC, et al. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost. 2014;12:488–496. doi:10.1111/jth.12506
   PubMed Web of Science ®Google Scholar
• Konkle BA, Stasyshyn O, Chowdary P, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 2015;126:1078–1085. doi:10.1182/blood-2015-03-630897
   PubMed Web of Science ®Google Scholar
• Klamroth R, Simpson M, von Depka-prondzinski M, et al. Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate®) in patients with severe haemophilia A. Haemophilia. 2016;22:730–738. doi:10.1111/hae.12985
   PubMed Web of Science ®Google Scholar
• Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood. 2012;119:3031–3037. doi:10.1182/blood-2011-09-382846
   PubMed Web of Science ®Google Scholar
• Klukowska A, Szczepański T, Vdovin V, et al. Long-term tolerability, immunogenicity and efficacy of Nuwiq® (human-cl rhFVIII) in children with severe haemophilia A. Haemophilia. 2018;24:595–603. doi:10.1111/hae.13460
   PubMed Web of Science ®Google Scholar
• Hershfield MS, Buckley RH, Greenberg ML, et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med. 1987;316(10):589–596. doi:10.1056/NEJM198703053161005
   PubMed Web of Science ®Google Scholar
• Clark R, Olson K, Fuh G, et al. Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem. 1996;271:21969–21977. doi:10.1074/jbc.271.36.21969
   PubMed Web of Science ®Google Scholar
• Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003;10:298–305. doi:10.1046/j.1365-2893.2003.00450.x
   PubMed Web of Science ®Google Scholar
• Palumbo E. PEG-interferon in acute and chronic hepatitis C: a review. Am J Ther. 2009;16:573–578. doi:10.1097/MJT.0b013e3181960819
   Web of Science ®Google Scholar
• Yee A, Gildersleeve RD, Gu S, et al. A von Willebrand factor fragment containing the D’D3 domains is sufficient to stabilize coagulation factor VIII in mice. Blood. 2014;124:445–452. doi:10.1182/blood-2013-11-540534
   PubMed Web of Science ®Google Scholar
• Gringeri A, Mantovani LG, Scalone L, Mannucci PM; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study. Blood. 2003;102:2358–2363. doi:10.1182/blood-2003-03-0941
   PubMed Web of Science ®Google Scholar
• Nogami K, Shima M. Phenotypic heterogeneity of hemostasis in severe hemophilia. Semin Thromb Hemost. 2015;41:826–831. doi:10.1055/s-0034-1395349
   PubMed Web of Science ®Google Scholar
• Jayandharan GR, Srivastava A. The phenotypic heterogeneity of severe hemophilia. Semin Thromb Hemost. 2008;34:128–141. doi:10.1055/s-2008-1066024
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Igawa T, Sampei Z, et al. A bis- pecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18:1570–1574. doi:10.1038/nm.2942
   PubMed Web of Science ®Google Scholar
• Sehgal A, Barros S, Ivanciu L, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med. 2015;21:492–497. doi:10.1038/nm.3847
   PubMed Web of Science ®Google Scholar
• Hilden I, Lauritzen B, Sørensen BB, et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood. 2012;119:5871–5878. doi:10.1182/blood-2012-01-401620
   PubMed Web of Science ®Google Scholar
• Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it compare to factor VIII? Blood. 2017;130:2463–2468. doi:10.1182/blood-2017-08-801662
   PubMed Web of Science ®Google Scholar
• Uchida N, Sambe T, Yoneyama K, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016;127:1633–1641. doi:10.1182/blood-2015-06-650226
   PubMed Web of Science ®Google Scholar
• Ragni MV. Targeting antithrombin to treat hemophilia. N Engl J Med. 2015;373:389–391. doi:10.1056/NEJMcibr1505657
   PubMed Web of Science ®Google Scholar
• Muczynski V, Christophe OD, Denis CV, Lenting PJ. Emerging therapeutic strategies in the treatment of hemophilia A. Semin Thromb Hemost. 2017;43:581–590. doi:10.1055/s-0037-1604053
   Web of Science ®Google Scholar
• Bolliger D, Szlam F, Suzuki N, et al. Heterozygous antithrombin deficiency improves in vivo hemostasis in factor VIII-deficient mice. Thromb Haemost. 2010;103:1233–1238. doi:10.1160/TH09-10-0732
   PubMed Web of Science ®Google Scholar
• Broze GJ, Warren LA, Novotny WF, et al. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood. 1988;71:335–343. doi:10.1182/blood.V71.2.335.335
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med. 2017;377:819–828. doi:10.1056/NEJMoa1616569
   PubMed Web of Science ®Google Scholar
• Chowdary P, Lethagen S, Friedrich U, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015;13:743–754. doi:10.1111/jth.12864
   PubMed Web of Science ®Google Scholar
• Eichler H, Angchaisuksiri P, Kavakli K, et al. A randomized trial of safety, pharmacokinetics, and pharmacodynamics of concizumab in people with hemophilia A. J Thromb Haemost. 2018;16:2184–2195. doi:10.1111/jth.14272
   PubMed Web of Science ®Google Scholar
• Shapiro AD, Angchaisuksiri P, Astermark J, et al. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 2019;134:1973–1982. doi:10.1182/blood.2019001542
   PubMed Web of Science ®Google Scholar
• Figueiredo M. Novo Nordisk Pauses 3 Clinical Trials of Concizumab Amid Safety Concerns. Hemophilia News Today. March 18, 2020. Available from: https://hemophilianewstoday.com/2020/08/14/novo-nordisk-resumes-phase-3-trials-of-concizumab-in-hemophilia-a-and-b/. Accessed May 22, 2021.
   Google Scholar
• Ray F. Novo Nordisk Resumes Phase 3 Trials of Concizumab in Hemophilia A and B. Hemophilia News Today. August 14, 2020. Available from: https://hemophilianewstoday.com/2020/08/14/novo-nordisk-resumes-phase-3-trials-of-concizumab-in-hemophilia-a-and-b/. Accessed May 22, 2021.
   Google Scholar
• Valentino LA, Khair K. Prophylaxis for hemophilia A without inhibitors: treatment options and considerations. Expert Rev Hematol. 2020;13:731–743. doi:10.1080/17474086.2020.1775576
   PubMed Web of Science ®Google Scholar
• Skinner MW, Nugent D, Wilton P, et al. Achieving the unimaginable: health equity in haemophilia. Haemophilia. 2020;26:17–24. Review. doi:10.1111/hae.13862
   PubMed Web of Science ®Google Scholar
• Iorio A, Skinner MW, Clearfield E, et al. Core outcome set for gene therapy in haemophilia: results of the coreHEM multistakeholder project. Haemophilia. 2018;24:e167–e172. doi:10.1111/hae.13504
   PubMed Web of Science ®Google Scholar
• Sidonio RF Jr, Pipe SW, Callaghan MU, et al. Discussing investigational AAV gene therapy with hemophilia patients: a guide. Blood Rev. 2020:100759. PMID: 33183859 Review. doi:10.1016/j.blre.2020.100759
   Web of Science ®Google Scholar